New gene therapy tested for Tough-to-Treat lung cancer
NCT ID NCT04911166
Summary
This early-stage study tested the safety of combining an existing immunotherapy drug (atezolizumab) with a new gene therapy (ADV/IL-12) for patients with advanced non-small cell lung cancer. The trial was for people whose cancer had continued to grow despite receiving standard first-line treatments. The main goal was to see if the two treatments could be given together safely and to look for early signs that they might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.